

Statistics

Corporate Backgrounder/June 2008

Ticker symbol:	Singapore: B20	Market capitalization:	\$537.5 million
URL:	www.biosensorsintl.com	Average daily volume:	8,581,150
Recent price range:	US\$0.43 – 0.81	Weighted average number of fully diluted shares:	1,053,926,000
Price as of 5/30/08:	US\$0.51	Next expected earnings date:	August
Fiscal year ends:	March 31		

Year Ended: March 31

(000's omitted except per share data; in US dollars)

	Three Months Ended		Year Ended	
	3/31/08	3/31/07	3/31/08	3/31/07
Total revenues	\$11,934	\$9,675	\$44,319	\$34,353
Gross profit	\$4,418	\$3,706	\$20,606	\$14,293
Loss from operations	\$(12,646)	\$(13,334)	\$(36,974)	\$(40,255)
Net loss	\$(19,151)	\$(9,993)	\$(30,005)	\$(36,293)
Diluted profit (loss) per share	\$(0.02)	\$(0.01)	\$(0.03)	\$(0.04)
Weighted average number of shares – diluted	1,053,926	913,832	985,119	909,940

Analyst Coverage

Lim Jit Soon, CITIGROUP
Pyari Menon, DEUTSCHE BANK
Gaurang Bhatia, UBS

DU JINSONG, CSFB
Kelly Chia, OCBC INVESTMENT RESEARCH

The projections, analyses and opinions presented in these analysts' reports are those of the author and are not endorsed or adopted by B20.si

Business Summary

Biosensors International Group, Ltd. (Singapore:B20) develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors believes it is well-positioned to be a leader in drug-eluting stents (DES), a therapy for heart disease that is rapidly gaining market share from traditional therapies such as bare-metal stenting and open-heart surgery. The Company has internally developed technology to address each component of a DES system, including the stent, delivery catheter, polymer and proprietary drug.

In addition to the DES products, Biosensors sells a number of products in the interventional cardiology and critical care markets. These include bare-metal stents, stent delivery systems, and a variety of specialty catheters and transducers. Biosensors has offices in Singapore, USA, Japan, Europe, Malaysia and the PRC, and manufacturing operations in Singapore, the Netherlands and the PRC.

Outlook

Interventional Cardiology has been perhaps the fastest-growing cardiovascular specialty in the past 20 years. Developments in interventional and minimally invasive treatments of heart disease have created multi-billion dollar markets including angioplasty, stenting and coronary bypass surgery. Biosensors is positioned to take its place in this large and growing market as it brings two DES products to market. Biosensors has received CE Mark approval for its **Axxion™** drug-eluting stent system, which incorporates its Calix stent, Senso stent delivery catheter and the commercially available drug, Paclitaxel. Its next generation DES, **BioMatrix®**, is currently undergoing clinical trials to support regulatory approval. BioMatrix is an innovative DES that incorporates the Biosensors S-Stent, Senso stent delivery catheter, proprietary bioresorbable polymer and proprietary anti-restenotic drug, Biolimus A9®. The integrated approach represented by BioMatrix is not common in the DES market and may provide Biosensors an advantage over competitors who must in-license various aspects of their systems. A CE Mark application has been filed for the BioMatrix system.

In addition to plans for marketing directly to physicians, Biosensors has also licensed aspects of its proprietary DES technology to third parties, including Terumo Corporation, Guidant Corporation and speciality-stent providers Devax, Inc. and Xtent, Inc. From those relationships, the Company derives licensing revenue from milestone payments and expects to derive licensing revenue from royalties and revenue-sharing from sales of third-party products.

Recent Developments

- **26 May** – Biosensors announced financial results for the fourth fiscal quarter (“4Q FY08”) and the twelve months ended 31 March 2008. Product revenues were US\$11.7 million for 4Q FY08 compared to US\$9.6 million for the same period in the prior year, an increase of 22 percent. For the twelve months ended 31 March 2008, product revenues were US\$38.7 million compared to US\$34.0 million for the prior year, an increase of 14 percent. For the quarter under review, the Group reported a net loss of US\$19.2 million or 1.82 US cent loss per basic and diluted share, compared to a net loss of US\$10.0 million or 1.09 US cent loss per basic and diluted share for the prior year’s corresponding period. For the fiscal year, the Group reported a net loss of US\$30.0 million or 3.05 US cent loss per basic and diluted share compared to a net loss of US\$36.3 million or 3.99 US cent loss per basic and diluted share for the prior year.
- **22 April** – Biosensors announced that its subsidiary, Biosensors Europe SA (“BESA”), has signed a modification to the license agreement with Terumo Corporation, amending the original agreement entered into in October 2003. Under the original agreement, Terumo was granted a license to develop, manufacture, market and sell drug-eluting stent systems incorporating Biosensors’ BioMatrix drug-eluting stent technologies. Terumo’s rights to market and sell their recently approved NOBORI[®] drug-eluting stent system are exclusive in Japan and non-exclusive elsewhere, except the United States where Biosensors retains all rights. As previously disclosed, Terumo has paid Biosensors’ entities a total of US\$14.0 million in milestone payments and is required to share future revenues with BESA over the term of the agreement, which is five years after initial launch of the NOBORI drug-eluting stent.
- **3 April** – Biosensors announced the full launch of its BioMatrix drug-eluting stent system in major European markets as well as in key markets in the Middle East, Africa and Asia. Developed internally by Biosensors, BioMatrix is a unique drug-eluting stent system that combines a biodegradable polymer and the company’s proprietary limus drug, Biolimus A9. The Company received CE Mark for BioMatrix in January 2008.
- **10 March** – Biosensors announced that two patients suffering from complex heart disease were implanted with the Company’s CE-certified BioMatrix drug-eluting stents by leading cardiologists, Prof. Eberhard Grube and Dr Kuzuaki Mitsudo, on the opening day of Singapore Live 2008 (“Sing Live”), an international conference organized by the Singapore National Heart Center and attended by leading cardiologists from Asia, Europe and the U.S.
- **3 March** – Biosensors announced the start of enrollment in the BEACON II registry program which plans to enroll 1,000 patients in 15 centers across Asia, including Singapore, Malaysia, Indonesia, Thailand, Australia, and New Zealand. A registry program enlists clinicians to document the performance of a specific therapy for a particular disease or condition. In BEACON II, clinicians will collect and analyze “real-world” use and clinical performance of the BioMatrix[™] Drug-Eluting Stent that are implanted in patients in paid-procedures performed by cardiologists at the participating centers.
- **18 February** – Biosensors announced that BioMatrix was successfully implanted into the first European patients following its Conformité Européenne (CE) Mark approval in January. Two leading cardiologists implanted a total of six BioMatrix drug-eluting stents in three complex cases that were broadcast live during the Joint Interventional Meeting 2008 (JIM). JIM is a leading meeting of interventional cardiologists held annually and attended by cardiologists and physicians from around the world. This scientific meeting, held in Rome, Italy, from 13 – 15 February, focused on live demonstration of interventional procedures.
- **24 January** – Biosensors announced the appointment of Mr. R. Michael Kleine as President and Chief Executive Officer reporting to the Board of Directors. Mr. Kleine succeeds Mr. Yoh Chie Lu as part of a planned transition to the Company’s next stage of growth in commercializing its drug-eluting stent technologies and will have responsibility for all departments, worldwide. Mr. Lu will continue as the Chairman of the Board of Directors and along with Mr. Kleine, will focus on formalizing strategic directions and guiding corporate developments with the aim to enhancing value for the Company and its shareholders.

Financial Highlights

Fiscal Year Ended: March 31

(000's omitted except per share data, in US dollars)

	2008	2007	2006	2005
Revenue	\$44,319	\$34,353	\$37,853	\$70,971
Net profit (loss)	\$(30,005)	\$(36,293)	\$(22,453)	\$21,087
Net profit (loss) per share - diluted	\$(0.03)	\$(0.04)	\$(0.03)	\$0.03
Weighted average shares - diluted	985,119	909,940	860,663	735,145

Corporate Information

US HEADQUARTERS:

20280 Acacia Street, Suite 300,
Newport Beach, CA 92660, U.S.A.

www.biosensorsintl.com

OFFICERS:

Yoh-Chie Lu
Chairman

R. Michael Kleine
President & CEO

Kevin R. Sayer
CFO

John Shulze
CTO

Loh Chee Mun
Sr. Vice President

Chart provided by Yahoo.com

